Valganciclovir in cytomegalovirus prophylaxis in renal transplant recipients
- Authors: Prokopenko E.I1, Shcherbakova E.O1, Vatazin A.V1, Yankovski A.G1, Pasov S.A1, Stepanov V.A1, Artemov D.V1
-
Affiliations:
- Issue: No 5 (2013)
- Pages: 37-41
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/261854
- ID: 261854
Cite item
Abstract
Full Text
About the authors
E. I Prokopenko
Email: RENALNEPHR0N@GMAIL.COM
E. O Shcherbakova
A. V Vatazin
A. G Yankovski
S. A Pasov
V. A Stepanov
D. V Artemov
References
- Очерки клинической трансплантологии / Под ред. С.В. Готье. М. — Тверь, ООО «Издательство «Триада», 2009. 360 с.
- Трансплантация почки / Пер. с англ. под ред. Я.Г. Мойсюка. — М., ГЭОТАР-Медиа, 2013. 848 с.
- Harvala H., Stewart C., Muller K. et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy // J. Med. Virol. — 2013; 85(5):893-898.
- Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the ‘silo hypothesis’ // Curr. Opin. Infect. Dis. — 2007; 20: 399-407.
- Egli A., Binggeli S., Bodaghi S. et al. Cytomegalovirus and polyomavirus BK posttransplant // Nephrol. Dial. Transplant. — 2007; 22 (Suppl 8): viii72-viii82.
- Toupance O., Bouedjoro-Camus M.C., Carquin J. et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses// Transpl. Int. — 2000; 6: 413—419.
- Hjelmesaeth J., Muller F., Jenssen T. et al. Is there a link between cytomegalovirus infection and new-onsetpost transplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage // Nephrol. Dial. Transplant. — 2005; 20: 2311—2315.
- Courivaud C., Bamoulid J., Chalopin J.M. et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients // J. Infect. Dis. — 2013; 207(10):1569—1575.
- Fellay J., Venetz J.P., Pascual M. et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir // Am. J. Transplant. — 2005; 5 (7):1781—1782.
- Valentine V.G., Weill D., Lombard G.A. et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis// Am. J. Transplant. — 2007; 7 (S2): 505.
- Boudreault A.A., Xie H., Rakita R.M. et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis // Transpl. Infect. Dis. — 2011; 13(3): 244—249.
- Papasotiriou M., Papachristou E., Marangos M. et al. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient // Clin. Nephrol — 2013; 80(1):75—78.
- Humar A., Lebranchu Y., Vincenti F. et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients//Am. J. Transplant. — 2010; 10: 1228—1237.
- Luan F.L., Stuckey L.J., Park J.M. et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection // J. Am. Soc. Nephrol. — 2009; 20(11): 2449—2458.
- Witzke O., Hauser I.A., Bartels M. et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial // Transplantation. — 2012; 93(1): 61—68.